Again that's speculation assuming that the additional expenditure is not being met with additional growth. We should find out in early July whether such concerns are warranted, but they have a good track record of being pretty good at avoiding burning cash too fast. The launch of this device obviously required a lot more cash than usual, I would expect now that this device has been in the market for around a year that they'd now be generating revenues at a fast enough growth rate to offset additional expenditures and that the net loss would be improving towards a net profit (if not that would probably be a good reason for concern though). We actually saw this last year, with a steadily improving bottom line (albeit not enough to avoid needing to raise).
For this reason though the bottom line performance will be most important to me. They're targeting cash flow positive in FY25 so I'd really be expecting the bottom line to improve quite a bit, or your fear may be justified. Let's see what happens.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-3121
-
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
25.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.34M |
Open | High | Low | Value | Volume |
25.5¢ | 26.0¢ | 24.5¢ | $239.5K | 950.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20 | 25.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 162496 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20 | 0.255 |
3 | 253000 | 0.250 |
5 | 145569 | 0.245 |
10 | 347238 | 0.240 |
3 | 402000 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 162496 | 4 |
0.265 | 298136 | 4 |
0.270 | 141107 | 3 |
0.275 | 159822 | 3 |
0.280 | 134384 | 3 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
EYE (ASX) Chart |